M&A / Jazz’s $7.2 Billion GW Pharma Deal: A Major Boost for Cannabinoid Research
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
Heptares Therapeutics Ltd
Last updated: 13.02.2014
Address: 6 Henrietta Street
London
WC2E 8PU
Tel: +44 (0)20 7557 7500
Web: http://www.mvmlifescience.com/
Company description
Heptares is a drug discovery company creating new medicines targeting G-protein-coupled receptors (GPCRs).
The Company is currently leveraging its GPCR expertise and proprietary StaR® technology to build a pipeline of best-in-class and first-in-class GPCR-targeted medicines for the treatment of CNS, metabolic and other diseases.
Heptares Therapeutics Ltd has already four-year collaboration with AstraZeneca (2011), where they focused on developing small molecule and antibody candidates targeting specific GPCRs linked to CNS/pain, CV/metabolic and inflammatory disorders.
Also, an approximately $100 million drug discovery collaboration with Takeda (2011) focused on a GPCR linked to CNS disorders.
Moreover, $200 million alliance with the Novartis Option Fund (2009) focused on single GPCR target of strategic interest to Novartis. Novartis and Heptares jointly announced the successful first-ever stabilisation of this previously intractable GPCR using the Heptares technology.
Products and services
Heptares Therapeutics Ltd deploys structure-based drug discovery techniques to identify potent and selective drug candidates to previously undruggable targets. They develop small molecule and antibody candidates targeting specific GPCRs linked to CNS/pain, CV/metabolic and inflammatory disorders.
Related
UK / New Post-Brexit Regulatory Alliance with Australia, Canada, Singapore & Switzerland
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to…
UK-Japan FTA / Banishing UK Pharma's Brexit Blues
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed…
UK / MSD to Build USD 1.3 Billion London Research Hub in Boon for Post-Brexit Britain
US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central…
Opinion / 3 Ways the UK’s Pharma Sector is Driving Innovation
Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical…
News Roundup / UK Pharma May 2020
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British…
Coronavirus / GSK & Sanofi’s Unprecedented COVID-19 Vaccine Collaboration
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are…
The UK / The G7’s Hottest Life Science Investment Destination?
With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is…
Brexit / Uncertainty Still Reigns for UK Life Sciences
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British…
Biotech Funding / 2019 A Boom Year for UK Biotech, Despite Brexit Concerns
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019…
Cannabis / GW Pharma's CBD Drug Profits Soar in 2nd Quarter 2019
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019,…
Amryt: A Rare Disease Startup Going Global
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial…
